LTBP1-ALK: A Novel Fusion identified in malignant pleural effusions from a patient with advanced Lung Adenocarcinoma

ALK (Anaplastic lymphoma kinase) rearrangement is the second most common targetable oncogene-dirven gene in NSCLC. It is identified in approximately 3 –7% of NSCLC patients [1], and is highly sensitive to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, alectinib, ceritinib, brigatinib [2]. EML4-ALK rearrangement was firstly identified by Soda et al. in 2007 [3]. With the development of NGS, more and more novel ALK fusion partners have been identified, such as KIF5B, STRN, KLC1, TPR, HIP1, DCTN1, CMTR1, GCC2, SEC31A and so on.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research